$517.75−4.44 (−0.85%)
At close: Oct 1, 2026, 4:00 PM ET
Idexx Laboratories, Inc. · Overview
Industry: Drugs · see every company filed here →
Idexx Laboratories, Inc. scores 53/100. Mixed. Strongest on quality and growth, value is the soft spot, trading at 36× earnings versus 400 Healthcare peers.
Tenet Score · vs sector
n=400Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value28
Quality77
Health42
Growth65
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityBHealthDGrowthCMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
35.8×
price ÷ trailing EPS, Oct 1, 2026 close
P/B
25.3×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
9.5×
price to fiscal 2025 sales
ROE
74%
TTM through Jun 30, 2026
Operating margin
31.6%
fiscal 2025, before interest and tax
Net margin
25.0%
TTM through Jun 30, 2026
Current ratio
1.17
Jun 30, 2026 balance sheet
Net debt / EBITDA
0.4×Tenet-derived Total debt less cash and short-term investments, over EBITDA (operating income plus depreciation and amortisation) from the filed statements. Long-term investments are not counted as cash. For some companies they include marketable securities held for more than a year. Computed by Tenet from the filed statements (formula house-nde.v1), because the data vendor published no value for this year.
computed by Tenet from the filed statements
EPS CAGR 5y
+14.3%
trailing 5-year, per share
Market cap
$40.8B
large cap
Div yield
—
no yield on file
52-wk range
500.61 – 769.98
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
6 / 17
- ✓ Buffett Quality
- ✓ Piotroski F-Score
- ✓ Munger Compounders
- ~ Magic Formula
- ✕ Graham Defensive
- ✕ Lynch GARP
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC45%
Gross margin62%
Debt / equity0.60
Technical Analysis
Downtrend short-term signalvs 50-day−4.9%
vs 200-day−12.1%
RSI (14)44
News & Insights
Headlines are on the News tab.Dividends
Pays no dividend. Every dollar of profit is reinvested into the business.Ownership
95% institutional
13F flows & insider trades land here.
About Idexx Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold IDXX, and at what weight. Everything else on this page stays open.Create a free account